Cargando…

Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing

Detalles Bibliográficos
Autores principales:	Jan de Beur, Suzanne M., Miller, Paul D., Weber, Thomas J., Peacock, Munro, Insogna, Karl, Kumar, Rajiv, Rauch, Frank, Luca, Diana, Cimms, Tricia, Roberts, Mary Scott, Martin, Javier San, Carpenter, Thomas O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Reply Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290665/ https://www.ncbi.nlm.nih.gov/pubmed/34030212 http://dx.doi.org/10.1002/jbmr.4317

Ejemplares similares

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
por: Carpenter, Thomas O, et al.
Publicado: (2020)

OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study
por: Carpenter, Thomas, et al.
Publicado: (2022)

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
por: Jan De Beur, Suzanne, et al.
Publicado: (2019)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

Long-term use of burosumab for the treatment of tumor-induced osteomalacia
por: Crotti, C., et al.
Publicado: (2022)

Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment
por: Aliberti, L, et al.
Publicado: (2023)

Reply
por: Villa, E, et al.
Publicado: (2001)

In reply:
por: Starčević Čizmarević, Nada, et al.
Publicado: (2021)

The Authors’ Reply
por: Mallik, Sarmila, et al.
Publicado: (2012)

The authors’ reply
por: El-Kannishy, Ghada M.
Publicado: (2018)

The authors’ reply
por: Kim, Hyo Shik, et al.
Publicado: (2017)

Authors’ reply
por: Myrtennäs, Kerstin, et al.
Publicado: (2017)

The author’s reply
por: Park, Chun Soo
Publicado: (2022)

The author’s reply
por: Park, Hyung Joo
Publicado: (2022)

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
por: Amarnani, Raj, et al.
Publicado: (2020)

Reply to the Comment of G. Feulner
por: Weber, Werner
Publicado: (2011)

In Reply to: Fine Needle Aspiration
por: Ehsanbakhsh, Ali-Reza, et al.
Publicado: (2014)

Reply to the Comment by Littlechild and Isupov
por: Willetts, Andrew, et al.
Publicado: (2017)

Reply to “The Carotid Sinus as a Viscometer”
por: Lee, Ui Yun, et al.
Publicado: (2020)

Reply to ‘Management of noncompaction requires optimisation’
por: Gurunathan, Sothinathan, et al.
Publicado: (2019)

Reply to Davis, A.K. Monarchs Reared in Winter in California Are Not Large Enough to Be Migrants. Comment on “James et al. First Population Study on Winter Breeding Monarch Butterflies, Danaus plexippus (Lepidoptera: Nymphalidae) in the Urban South Bay of San Francisco, California. Insects 2021, 12, 946”
por: James, David G., et al.
Publicado: (2022)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report
por: Oe, Yuki, et al.
Publicado: (2021)

The Slopes Remain the Same: Reply to Wolfe (2016)
por: Kristjánsson, Árni
Publicado: (2016)

The Paradox of Ingestion of Dietary Cholesterol in “Vegans”—Reply
por: Clarys, Peter, et al.
Publicado: (2017)

Reply to “Dyslexia: Still Not a Neurodevelopmental Disorder”
por: Fraga González, Gorka, et al.
Publicado: (2019)

Authors’ Reply
por: Thomas, Emy, et al.
Publicado: (2016)

Reply to commentary on costs of diabetes and its complications in Poland
por: Leśniowska, Joanna
Publicado: (2014)

Correction to Figures: A Reply to Hwang and Peli (2014)
por: Gao, Zhongpai
Publicado: (2017)

Maximum Entropy Theory of Ecology: A Reply to Harte
por: Favretti, Marco
Publicado: (2018)

In reply to Unopposed Estrogen and Endometrial Cancer: Association or Causation?
por: Trkulja, Vladimir, et al.
Publicado: (2019)

Reply to Comment On: “Indirect Assessment of Skeletal Muscle Glycogen Content in Professional Soccer Players before and after a Match through a Non-Invasive Ultrasound Technology Nutrients 2020, 12(4), 971”
por: San-Millán, Iñigo, et al.
Publicado: (2020)

Reply to “Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma”
por: Hitu, Liviu, et al.
Publicado: (2020)

Visual Search Revived: The Slopes Are Not That Slippery: A Reply to Kristjansson (2015)
por: Wolfe, Jeremy M.
Publicado: (2016)

Reply to “Tolerogenic insulin peptide therapy precipitates type 1 diabetes”
por: Daniel, Carolin, et al.
Publicado: (2017)

Reply to “Predictors of Recurrence for T3a RCC: A Recurring Conundrum”
por: Miyake, Makito, et al.
Publicado: (2020)

Mitochondrial Functions, Cognition, and the Evolution of Intelligence: Reply to Commentaries and Moving Forward
por: Geary, David C.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dhge64k14cbvgdrr5ahgrnus8p